Data from multiple studies indicate a predictive role for EGFR-activating mutations with respect to response rate and progression-free survival with TKI therapy, particularly in the first-line setting.(4,13) Crizotinib is indicated for the treatment of patients with locally advanced or metastatic NSCLC that is anaplastic lymphoma kinase (ALK)-positive, which occurs in 1 to 7% of these patients.(26). This evidence concerns the gene ALK and non-small cell lung carcinoma.